SGTX
NASDAQSigilon Therapeutics Inc.
Latest news
25 items- 13D/GSEC Form SC 13G/A filed by Sigilon Therapeutics Inc. (Amendment)SC 13G/A - Sigilon Therapeutics, Inc. (0001821323) (Subject)
- SECSEC Form 15-12G filed by Sigilon Therapeutics Inc.15-12G - Sigilon Therapeutics, Inc. (0001821323) (Filer)
- SECSEC Form EFFECT filed by Sigilon Therapeutics Inc.EFFECT - Sigilon Therapeutics, Inc. (0001821323) (Filer)
- INSIDERSEC Form 4 filed by Flagship Ventures Fund V General Partner Llc4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
- NEWSOver $25M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are BuyingAlthough U.S. stocks closed mostly higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Royal Caribbean Cruises The Trade: Royal Caribbean Cruises Ltd. (NYSE:RCL) Director Maritza Gomez Montiel acquired a to
- 13D/GSEC Form SC 13D/A filed by Sigilon Therapeutics Inc. (Amendment)SC 13D/A - Sigilon Therapeutics, Inc. (0001821323) (Subject)
- INSIDERSEC Form 4: Eli Lilly & Co bought $25,639,916 worth of shares (1,718,493 units at $14.92)4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
- PRLilly Completes Acquisition of Sigilon TherapeuticsINDIANAPOLIS, Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ:SGTX). The acquisition allows Lilly to continue researching and developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. "Make life better – that's the phrase that guides everything we do at Lilly," said Ruth Gimeno, Ph.D., group vice president, diabetes, obesity and cardiometabolic research at Lilly. "We are excited to welcome our new colleagues from Sigilon to Lilly; together, we will strive to provide solutions for people living with type 1 diabetes that absolves them of cons
- SECSEC Form S-8 POS filed by Sigilon Therapeutics Inc.S-8 POS - Sigilon Therapeutics, Inc. (0001821323) (Filer)
- SECSEC Form S-8 POS filed by Sigilon Therapeutics Inc.S-8 POS - Sigilon Therapeutics, Inc. (0001821323) (Filer)
- SECSEC Form S-8 POS filed by Sigilon Therapeutics Inc.S-8 POS - Sigilon Therapeutics, Inc. (0001821323) (Filer)
- SECSEC Form S-8 POS filed by Sigilon Therapeutics Inc.S-8 POS - Sigilon Therapeutics, Inc. (0001821323) (Filer)
- SECSEC Form POS AM filed by Sigilon Therapeutics Inc.POS AM - Sigilon Therapeutics, Inc. (0001821323) (Filer)
- SECSigilon Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Sigilon Therapeutics, Inc. (0001821323) (Filer)
- INSIDERSEC Form 4 filed by Oesterle Stephen N.4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
- INSIDERSEC Form 4 filed by Cole Douglas G.4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
- INSIDERSEC Form 4: Cox John returned 341 shares to the company, closing all direct ownership in the company4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
- INSIDERSEC Form 4 filed by Shaff Eric D.4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
- INSIDERSEC Form 4: Yuan Qing Sarah returned 2,884 shares to the company, closing all direct ownership in the company4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
- INSIDERSEC Form 4: Kowalsky Matthew Paul returned 1,925 shares to the company, closing all direct ownership in the company4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
- INSIDERSEC Form 4 filed by Ashton-Rickardt Philip4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
- INSIDERSEC Form 4 filed by Patel Kavita4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
- INSIDERSEC Form 4 filed by Ruffolo Robert R4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
- INSIDERSEC Form 4: Vivaldi Coelho Rogerio returned 12,169 shares to the company, closing all direct ownership in the company4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
- INSIDERSEC Form 4: Pontes Josias returned 3,504 shares to the company, closing all direct ownership in the company4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
SGTX FAQ
7 questionsWhat does Sigilon Therapeutics Inc. do?
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream...Where does SGTX stock trade?
Sigilon Therapeutics Inc. (SGTX) is listed on NASDAQ.What sector and industry is SGTX in?
Sigilon Therapeutics Inc. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.When did Sigilon Therapeutics Inc. go public?
Sigilon Therapeutics Inc. (SGTX) completed its IPO in 2020.What are analysts saying about SGTX?
Sigilon Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $700.00 price target on 2021-12-23.What companies are similar to SGTX?
Notable peers in the same industry include PM (Philip Morris International Inc), BTI (British American Tobacco Industries p.l.c.), MO (Altria Group Inc.), RGC (Regencell Bioscience Holdings Limited), RLX (RLX Technology Inc.). Compare SGTX side-by-side with any of them on Quantisnow.How can I track SGTX on Quantisnow?
Quantisnow aggregates Sigilon Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SGTX to receive live email and push alerts on every new disclosure.